Skip to content

Physiotherapists' Placebo or Nocebo Communication Regarding VR

The Effect of Physiotherapists' Placebo or Nocebo Communication About Virtual Reality on Treatment Beliefs in Healthy People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06307912
Enrollment
126
Registered
2024-03-13
Start date
2023-11-01
Completion date
2023-12-01
Last updated
2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Communication

Brief summary

Rationale: Chronic musculoskeletal pain (CMP) is a common and disabling condition. Physiotherapy is the most frequently administered nonpharmacological treatment option for patients with CMP and recently virtual reality (VR) was introduced in physiotherapy care as a novel treatment modality. Proper communication about physiotherapy treatment (modalities) is important to improve treatment outcomes, by applying placebo effects enhancing communication and avoiding nocebo effects enhancing communication. However, yet is still unknown to what extent this applies to communication of physiotherapists about VR in healthy participants. Objective: To determine the effect of physiotherapists' placebo or nocebo therapeutic communication about VR, on treatment credibility and expectation in healthy participants. Study design: Web-based randomized controlled trial. Study population: 126 participants Intervention: The placebo intervention group will be shown an educational video about VR, containing placebo effects enhancing verbal language. The nocebo intervention group will be shown an educational video about VR, containing nocebo effects enhancing verbal language. Primary study parameters: The primary study parameters are treatment credibility and treatment expectation. Treatment credibility and treatment expectations will be measured using the Dutch credibility and expectancy questionnaire (CEQ).

Interventions

The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.

The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.

Sponsors

HAN University of Applied Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* aged ≥ 18 * access to the internet * provide informed consent

Exclusion criteria

* lacked comprehension of the Dutch language * had experience with therapeutic VR * suffers from CMP

Design outcomes

Primary

MeasureTime frameDescription
Change in treatment expectancy measured using the Credibility and Expectancy Questionnaire (CEQ)Baseline and immediately after the interventionThis questionnaire on treatment expectancy scores from 6 (lowest expectancy) to 54 (highest expectancy)
Change in treatment credibility measured using the Credibility and Expectancy Questionnaire (CEQ)Baseline and immediately after the interventionThis questionnaire on treatment credibility scores from 5 (lowest credibility) to 45 (highest credibility)

Secondary

MeasureTime frameDescription
Change in openness to VR measured using a single questionBaseline and immediately after the interventionThe question would you be open to treatment with therapeutic VR was scored with a yes/no

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026